Results 1 to 10 of about 23,073,058 (182)
PHARMACOECONOMIC ANALYSIS OF MARKET OF BIOLOGICALLY ACTIVE ADDITIVES MERCHANDIZED IN PHARMACY ORGANIZATIONS [PDF]
Фармация и фармакология (Пятигорск), 2015 The study focuses on the evaluation of the use of biologically active additives in pharmacies in Belgorod on the basis of pharmacoeconomic analyzes. We have identified preferred groups in terms of economic profitability.
O. V. Belousova +3 more
doaj +2 more sources
The economic impact of clinical pharmacists in a tertiary care centre in Germany: pharmacoeconomic benefit calculation using cost-avoidance analysis [PDF]
BMC Health Services ResearchObjective Pharmacoeconomic evaluation of clinical pharmacy services (CPS) aims to assess the contribution of clinical pharmacists (CP) to optimize the medication process by interventions while simultaneously saving costs.
Julia Borella +5 more
doaj +2 more sources
Modelling in economic evaluations of medicines [PDF]
Arhiv za farmaciju, 2021 Economic evaluation in health (also known as pharmacoeconomic in case of medicines) identifies, measures, and values costs and outcomes of alternative healthcare technologies, and can be performed alongside controlled clinical trials, but analytical ...
Lakić Dragana +3 more
doaj +1 more source
Фармацевтичний журнал, 2019 The introduction of various technologies for the prevention of chronic viral infections into practice requires well-founded evidence of their effectiveness, which can be obtained using pharmacoeconomic methods and models that determine not only the ...
S. O. Soloviov +2 more
doaj +1 more source
Current Status of Studies Measuring Health State Utility for 121 Rare Diseases
罕见病研究, 2023 Pharmacoeconomic evaluation is the essential supporting information for the inclusion of rare disease drugs into medical insurance in China. The accurate measurement of the health state utility of rare diseas is of practical significance to the ...
FENG Junchao +5 more
doaj +1 more source
BMC Medical Informatics and Decision Making, 2012 Background Due to escalating treatment costs, pharmacoeconomic analysis has been assigned a key role in the quest for increased efficiency in resource allocation for drug therapies in high-income countries.
Mori Amani, Robberstad Bjarne
doaj +1 more source
Клиническая онкогематология, 2015 Background. Second generation tyrosine kinase inhibitors (nilotinib and dasatinib) have advantages over imatinib in frequency and rate of cytogenetic and molecular responses obtaining in chronic myelogenous leukemia (CML) treatment.
Vasilii Anatol’evich Shuvaev +3 more
doaj +1 more source
Zaporožskij Medicinskij Žurnal, 2014 Cohort research based on 180 patients with hypertension treated in cardiological department was carried out in Vinnitsa regional hospital in 2011–2012. Pharmacoeconomic analysis of prevalent schemes of essential hypertension medication was done.
O. P. Balitska
doaj +1 more source
Cost Effectiveness and Resource Allocation, 2023 In recent years, international academics recognized that quality-adjusted life-years (QALYs) may not always fully capture the benefits produced by an intervention, and considered incorporating additional elements of value into cost-effectiveness analysis
Lihua Sun, Shiqi Li, Xiaochen Peng
doaj +1 more source
Качественная клиническая практика, 2019 Introduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim.
A. S. Kolbin +3 more
doaj +1 more source